Yujing Zhao1, Dana L Tudorascu2, Oscar L Lopez3,4, Ann D Cohen4, Chester A Mathis5, Howard J Aizenstein4, Julie C Price5,6, Lewis H Kuller7, M Ilyas Kamboh8, Steven T DeKosky9, William E Klunk3,4, Beth E Snitz3. 1. School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania. 2. Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania. 3. Department of Neurology, University of Pittsburgh, Pittsburgh, Pennsylvania. 4. Department of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania. 5. Department of Radiology, University of Pittsburgh, Pittsburgh, Pennsylvania. 6. now with the Department of Radiology, Massachusetts General Hospital, Boston. 7. Department of Epidemiology, University of Pittsburgh, Pittsburgh, Pennsylvania. 8. Department of Human Genetics, University of Pittsburgh, Pittsburgh, Pennsylvania. 9. Department of Neurology, University of Florida, Gainesville.
Abstract
Importance: The prevalence of pathologic conditions of the brain associated with Alzheimer disease increases strongly with age. Little is known about the distribution and clinical significance of preclinical biomarker staging in the oldest old, when most individuals without dementia are likely to have positive biomarkers. Objective: To compare the patterns of long-term cognitive decline in multiple domains by preclinical biomarker status in the oldest old without dementia. Design, Setting, and Participants: A longitudinal observational study with a mean (SD) of 12.2 (2.2) years (range 7.2-15.1 years) of follow-up was conducted in an academic medical center from August 24, 2000, to January 14, 2016, including and extending observations from the Ginkgo Evaluation of Memory study. A total of 197 adults who had completed the Ginkgo Evaluation of Memory study, were free of dementia, and were able to undergo magnetic resonance imaging were eligible for a neuroimaging study in 2009. Of these patients, 175 were included in the present analyses; 140 (80%) were cognitively normal and 35 (20%) had mild cognitive impairment. Main Outcomes and Measures: Biomarker groups included amyloid β negative (Aβ-)/neurodegeneration negative (ND-), amyloid β positive (Aβ+)/ND-, Aβ-/neurodegeneration positive (ND+), and Aβ+/ND+ based on Pittsburgh Compound B retention and hippocampal volume in 2009. Participants completed baseline neuropsychological testing from 2000 to 2002 and annual testing from 2004 to 2016. Domains included memory, executive function, language, visual-spatial reasoning, and attention and psychomotor speed. Slopes of decline were evaluated with linear mixed models adjusted for age, sex, and years of education. Results: Of the 175 participants (71 women and 104 men), at imaging, mean (SD) age was 86.0 (2.9) years (range, 82-95 years). A total of 42 participants (24.0%) were Aβ-/ND-, 32 (18.3%) were Aβ+/ND-, 35 (20.0%) were Aβ-/ND+, and 66 (37.7%) were Aβ+/ND+. On all cognitive measures, the Aβ+/ND+ group showed the steepest decline. Compared with the Aβ-/ND- group, the amyloid deposition alone (Aβ+/ND-) group showed faster decline on tests of verbal and visual memory (-0.3513; 95% CI, -0.5269 to -0.1756), executive function (0.0158; 95% CI, 0.0013-0.0303), and language (-0.1934; 95% CI, -0.3520 to -0.0348). The Aβ-/ND+ group showed faster visual memory decline than the Aβ-/ND- reference group (-0.3007; 95% CI, -0.4736 to -0.1279). Conclusions and Relevance: In the oldest old without dementia, presence of either or both Aβ and hippocampal atrophy is typical (>75%). Isolated hippocampal volume atrophy is associated only with greater decline in memory. However, isolated Aβ is associated with decline in memory plus language and executive functions. These findings suggest different underlying pathophysiologic processes in the Aβ+/ND- and Aβ-/ND+ groups.
Importance: The prevalence of pathologic conditions of the brain associated with Alzheimer disease increases strongly with age. Little is known about the distribution and clinical significance of preclinical biomarker staging in the oldest old, when most individuals without dementia are likely to have positive biomarkers. Objective: To compare the patterns of long-term cognitive decline in multiple domains by preclinical biomarker status in the oldest old without dementia. Design, Setting, and Participants: A longitudinal observational study with a mean (SD) of 12.2 (2.2) years (range 7.2-15.1 years) of follow-up was conducted in an academic medical center from August 24, 2000, to January 14, 2016, including and extending observations from the Ginkgo Evaluation of Memory study. A total of 197 adults who had completed the Ginkgo Evaluation of Memory study, were free of dementia, and were able to undergo magnetic resonance imaging were eligible for a neuroimaging study in 2009. Of these patients, 175 were included in the present analyses; 140 (80%) were cognitively normal and 35 (20%) had mild cognitive impairment. Main Outcomes and Measures: Biomarker groups included amyloid β negative (Aβ-)/neurodegeneration negative (ND-), amyloid β positive (Aβ+)/ND-, Aβ-/neurodegeneration positive (ND+), and Aβ+/ND+ based on Pittsburgh Compound B retention and hippocampal volume in 2009. Participants completed baseline neuropsychological testing from 2000 to 2002 and annual testing from 2004 to 2016. Domains included memory, executive function, language, visual-spatial reasoning, and attention and psychomotor speed. Slopes of decline were evaluated with linear mixed models adjusted for age, sex, and years of education. Results: Of the 175 participants (71 women and 104 men), at imaging, mean (SD) age was 86.0 (2.9) years (range, 82-95 years). A total of 42 participants (24.0%) were Aβ-/ND-, 32 (18.3%) were Aβ+/ND-, 35 (20.0%) were Aβ-/ND+, and 66 (37.7%) were Aβ+/ND+. On all cognitive measures, the Aβ+/ND+ group showed the steepest decline. Compared with the Aβ-/ND- group, the amyloid deposition alone (Aβ+/ND-) group showed faster decline on tests of verbal and visual memory (-0.3513; 95% CI, -0.5269 to -0.1756), executive function (0.0158; 95% CI, 0.0013-0.0303), and language (-0.1934; 95% CI, -0.3520 to -0.0348). The Aβ-/ND+ group showed faster visual memory decline than the Aβ-/ND- reference group (-0.3007; 95% CI, -0.4736 to -0.1279). Conclusions and Relevance: In the oldest old without dementia, presence of either or both Aβ and hippocampal atrophy is typical (>75%). Isolated hippocampal volume atrophy is associated only with greater decline in memory. However, isolated Aβ is associated with decline in memory plus language and executive functions. These findings suggest different underlying pathophysiologic processes in the Aβ+/ND- and Aβ-/ND+ groups.
Authors: Stephanie Jb Vos; Chengjie Xiong; Pieter Jelle Visser; Mateusz S Jasielec; Jason Hassenstab; Elizabeth A Grant; Nigel J Cairns; John C Morris; David M Holtzman; Anne M Fagan Journal: Lancet Neurol Date: 2013-09-04 Impact factor: 44.182
Authors: Joshua A Sonnen; Karen Santa Cruz; Laura S Hemmy; Randall Woltjer; James B Leverenz; Kathleen S Montine; Clifford R Jack; Jeffrey Kaye; Kelvin Lim; Eric B Larson; Lon White; Thomas J Montine Journal: Arch Neurol Date: 2011-08
Authors: J L Whitwell; C R Jack; J E Parisi; M L Senjem; D S Knopman; B F Boeve; R Rademakers; M Baker; R C Petersen; D W Dickson; K A Josephs Journal: Neurology Date: 2010-12-14 Impact factor: 9.910
Authors: Miranka Wirth; Hwamee Oh; Elizabeth C Mormino; Candace Markley; Susan M Landau; William J Jagust Journal: Alzheimers Dement Date: 2013-03-07 Impact factor: 21.566
Authors: Steven T DeKosky; Jeff D Williamson; Annette L Fitzpatrick; Richard A Kronmal; Diane G Ives; Judith A Saxton; Oscar L Lopez; Gregory Burke; Michelle C Carlson; Linda P Fried; Lewis H Kuller; John A Robbins; Russell P Tracy; Nancy F Woolard; Leslie Dunn; Beth E Snitz; Richard L Nahin; Curt D Furberg Journal: JAMA Date: 2008-11-19 Impact factor: 56.272
Authors: Clifford R Jack; Heather J Wiste; Stephen D Weigand; Walter A Rocca; David S Knopman; Michelle M Mielke; Val J Lowe; Matthew L Senjem; Jeffrey L Gunter; Gregory M Preboske; Vernon S Pankratz; Prashanthi Vemuri; Ronald C Petersen Journal: Lancet Neurol Date: 2014-09-04 Impact factor: 44.182
Authors: Oscar L Lopez; William E Klunk; Chester Mathis; Rhaven L Coleman; Julie Price; James T Becker; Howard J Aizenstein; Beth Snitz; Ann Cohen; Milos Ikonomovic; Eric McDade; Steven T DeKosky; Lisa Weissfeld; Lewis H Kuller Journal: Neurology Date: 2014-10-10 Impact factor: 9.910
Authors: Howard Jay Aizenstein; Robert D Nebes; Judith A Saxton; Julie C Price; Chester A Mathis; Nicholas D Tsopelas; Scott K Ziolko; Jeffrey A James; Beth E Snitz; Patricia R Houck; Wenzhu Bi; Ann D Cohen; Brian J Lopresti; Steven T DeKosky; Edythe M Halligan; William E Klunk Journal: Arch Neurol Date: 2008-11
Authors: Clifford R Jack; Heather J Wiste; David S Knopman; Prashanthi Vemuri; Michelle M Mielke; Stephen D Weigand; Matthew L Senjem; Jeffrey L Gunter; Val Lowe; Brian E Gregg; Vernon S Pankratz; Ronald C Petersen Journal: Neurology Date: 2014-04-04 Impact factor: 9.910
Authors: Murat Bilgel; Lori Beason-Held; Yang An; Yun Zhou; Dean F Wong; Susan M Resnick Journal: J Cereb Blood Flow Metab Date: 2019-02-12 Impact factor: 6.200
Authors: Eider M Arenaza-Urquijo; Scott A Przybelski; Timothy L Lesnick; Jonathan Graff-Radford; Mary M Machulda; David S Knopman; Christopher G Schwarz; Val J Lowe; Michelle M Mielke; Ronald C Petersen; Clifford R Jack; Prashanthi Vemuri Journal: Brain Date: 2019-04-01 Impact factor: 13.501
Authors: Murat Bilgel; Yang An; Jessica Helphrey; Wendy Elkins; Gabriela Gomez; Dean F Wong; Christos Davatzikos; Luigi Ferrucci; Susan M Resnick Journal: Brain Date: 2018-08-01 Impact factor: 13.501
Authors: Davis C Woodworth; Kiana A Scambray; María M Corrada; Claudia H Kawas; S Ahmad Sajjadi Journal: J Alzheimers Dis Date: 2021 Impact factor: 4.472
Authors: Lauren E Oberlin; Kirk I Erickson; Rachel Mackey; William E Klunk; Howard Aizenstein; Brian J Lopresti; Lewis H Kuller; Oscar L Lopez; Beth E Snitz Journal: Brain Behav Immun Date: 2021-03-15 Impact factor: 19.227
Authors: Oscar L Lopez; James T Becker; YueFang Chang; William E Klunk; Chester Mathis; Julia Price; Howard J Aizenstein; Beth Snitz; Ann D Cohen; Steven T DeKosky; Milos Ikonomovic; M Ilyas Kamboh; Lewis H Kuller Journal: Neurology Date: 2018-04-25 Impact factor: 9.910